RNA Medicines: Can Nanoparticles Target

Why does RNA drug delivery matter as manufacturing expands?

IndexBox's forecast links demand for nucleic acid ingredients to expanding vaccine, gene therapy and gene-editing applications. That commercial outlook raises a practical pharmaceutical question: how much of a manufactured RNA dose reaches its intended destination? The forecast describes anticipated market demand; it does not establish that any experimental treatment improves patient outcomes. [IndexBox market forecast](https://www.indexbox.io/blog/nucleic-acid-raw-materials-market-forecast-to-2035-growth-accelerates-on-mrna-vaccine-and-gene-therapy-demand/)

Delivery involves barriers even after a particle enters a cell. RNA can become trapped in membrane-bound compartments called endosomes, limiting access to the cellular machinery needed for its effect. In a 2013 laboratory and mouse study, Gilleron and colleagues found that only a small fraction of the small interfering RNA carried by their lipid nanoparticles escaped into the surrounding cell fluid. This finding concerns the formulations and experimental conditions studied; it is not a universal efficiency estimate for RNA medicines. [Nature Biotechnology study](https://www.nature.com/articles/nbt.2612)

Which approved treatment shows that lipid-based RNA delivery works?

Patisiran, marketed as Onpattro, received initial US approval in 2018. Its prescribing information describes a lipid complex designed to deliver small interfering RNA, or siRNA, to hepatocytes, the main functional cells of the liver. The RNA reduces production of transthyretin, a protein involved in the disease. This is an RNA-silencing treatment: it directs the breakdown of a specific messenger RNA rather than supplying instructions to manufacture a replacement protein. [Onpattro prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e87ec36f-b4b4-49d4-aea4-d4ffb09b0970)

The treatment also illustrates why delivery must be evaluated alongside tolerability. Its label requires premedication and monitoring because infusion-related reactions can occur. For developers, the clinical lesson is that a delivery system must support useful drug activity at an acceptable level of risk; demonstrating that particles enter cells is only one part of that assessment. [Onpattro safety information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e87ec36f-b4b4-49d4-aea4-d4ffb09b0970)

Can nanoparticles deliver RNA to organs beyond the liver?

A 2020 study by Cheng and colleagues introduced selective organ targeting, or SORT. Researchers adjusted lipid nanoparticle formulations to direct RNA delivery and gene-editing activity toward the lungs, spleen or liver in mice. The experiments showed that the carrier's composition could influence where its genetic cargo worked. This was a preclinical demonstration, not evidence that the tested formulations treated patients. [Nature Nanotechnology study](https://www.nature.com/articles/s41565-020-0669-6)

The implication is that delivery chemistry could help broaden the tissues reachable by RNA medicines. Translating that possibility into treatment requires evidence about which cells receive an active dose, how long the effect lasts, and what happens elsewhere in the body. Human studies must then establish meaningful clinical benefit and characterize adverse effects. Increasing supplies of RNA ingredients can support development, but the success of an individual medicine still depends on its delivery system and clinical results.